Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 1—January 2007

Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*Comments to Author , Erik J. Dasbach*, and Ralph P. Insinga*
Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Table 3

Incremental cost-effectiveness ratios of alternative HPV vaccination strategies with varying start age of vaccination*

StrategyDiscounted total
Incremental
CostsQALY$/QALY†
18-y-old women plus 18- to 24-y-old female catch-up73,553,8472,699,1921,858
15-y-old female adolescents plus 15- to 24-y-old female catch-up73,895,0462,699,214Weakly dominated
12-y-old girls plus 12- to 24-y-old female catch-up74,815,6672,699,3438,357
18-y-old women and men plus 18- to 24-y-old female and male catch-up77,535,3832,699,385Weakly dominated
15-y-old female and male adolescents plus 15- to 24-y-old female and male catch-up78,455,7502,699,404Weakly dominated
12-y-old female and male adolescents plus 12- to 24-y-old female and male catch-up program81,761,2102,699,50642,697

*Assumes cost of vaccination series is US $360, duration of protection is lifelong, and coverage rate of 50% among age 15- to 24-y-olds. HPV, human papillomavirus; QALY, quality-adjusted life years.
†Compared with the preceding nondominated strategy. Strategy A is dominated if there is another strategy, B, that is more effective and less costly than strategy A. A strategy is weakly dominated if there is another more effective program that has a incremental cost-effectiveness ratio.

Main Article

TOP